In recent years, under the background of the intensification of pharmaceutical reform and the trend of innovation, the R&D investment of pharmaceutical companies is increasing
year by year.
Data show that from 2016 to 2021, global pharmaceutical R&D expenditure has risen from US$160 billion to US$212 billion, with a compound annual growth rate of 5.
8%.
In China, behind the progress of clinical and marketing of new drugs, it is also inseparable from the continuous high R&D investment
of pharmaceutical companies.
It is understood that in the process of accelerating innovation and transforming into innovative pharmaceutical companies, the R&D investment of many domestic pharmaceutical companies has been increasing
year by year.
Taking Hengrui Pharmaceutical as an example, its R&D investment has risen rapidly from 1.
18 billion yuan in 2016 to 6.
203 billion yuan
in 2021.
In the first three quarters of this year, R&D expenses reached 3.
498 billion yuan
.
It is estimated that together with the new development expenditure in this period, Hengrui Pharmaceutical's R&D investment exceeds 4.
5 billion yuan.
In addition to Hengrui Pharmaceutical, the R&D investment of Aosaikang in the same period from 2020 to 2022 was 220 million yuan, 207 million yuan and 251 million yuan, accounting for 13.
32%, 12.
34% and 24.
81% of the operating income, respectively, accounting for an increase
year by year.
In the first four months of 2020, 2021 and 2022, Biocytogen invested RMB276 million, RMB558 million and RMB212
million respectively.
Longjin Pharmaceutical's R&D expenses in the first three quarters of 2022 were 15.
129 million yuan, a year-on-year increase of 30.
98%, the company said that it was mainly due to the increase in R&D expenditure on chemical class 1 new drugs and the increase
in R&D expenditure on chemical generic drugs.
Fosun Pharma's R&D investment in the first three quarters of 2022 totaled RMB3.
761 billion, a year-on-year increase of 19.
36%; Among them, R&D expenses were 2.
849 billion yuan, a year-on-year increase of 435 million yuan, an increase of 18.
02%.
In addition, Rico Biotech's R&D expenses in 2021 also increased very brightly, with R&D investment of 473 million yuan in 2021, a year-on-year increase of 262.
08%; Through continuous increase in drug R&D investment, Enhua Pharmaceutical's development strategy of separating and paying equal attention to imitation and imitation, the R&D expenditure in 2021 increased by 50.
89%
compared with the same period of the previous year.
At present, in the context of continuous increase in R&D investment, a large number of pharmaceutical companies have begun to enter the harvest period
.
For example, up to now, Hengrui Pharmaceutical has approved 11 innovative drugs for marketing, ranking among the best
in the same industry in China.
Among them, in July this year, Hengrui Pharmaceutical's 11th listed innovative drug and the first independently developed androgen receptor (AR) inhibitor in China, Erien (Revirutamide tablets), issued the first prescription in China, bringing new treatment options
for metastatic hormone-sensitive prostate cancer patients with high tumor burden in China.
In recent years, CP Tianqing has been building its own pipeline moat
in the way of "self-research + cooperation".
At present, in terms of innovative drugs, the company has 77 new drugs (61 Class 1 new drugs) in the clinical application stage and above, of which 14 new drugs (5 Class 1 new drugs) are in the stage III and above, and 7 biosimilars focus on global blockbuster varieties
.
In addition, in the context of insisting on innovative R&D investment, Aosaikang has also achieved key milestones in a number of R&D projects during the reporting period
.
There are 45 main research projects, and 11 key chemical and biological innovative drugs under research have been publicly disclosed, of which 3 biological innovative drugs independently developed by the company and with independent intellectual property rights are among the top three in China, showing good self-research capabilities
in the field of biological innovative drugs.
In general, the R&D investment of China's pharmaceutical enterprises is continuing to increase, such as 2020 compared with 2016, which has increased by nearly 4 times
.
The industry expects that with continuous investment, the gap between China's new drug research and development and the world will gradually narrow, and the domestic pharmaceutical innovation industry will also accelerate on the road
of higher quality development.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
